A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Saved in:
| Title: | A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. |
|---|---|
| Authors: | Leblond, Véronique1 (AUTHOR), Morel, Pierre2,3,4 (AUTHOR) pimorel@nordnet.fr, Dilhuidy, Marie-Sarah5 (AUTHOR), Leleu, Xavier6 (AUTHOR), Soussain, Carole7,8 (AUTHOR), Leprête, Stéphane9 (AUTHOR), Dreyfus, Brigitte10 (AUTHOR), Dartigeas, Caroline11 (AUTHOR), Mahé, Béatrice12 (AUTHOR), Anglaret, Bruno13 (AUTHOR), Pégourié, Brigitte14 (AUTHOR), Besson, Caroline15 (AUTHOR), Aurran, Thérèse16 (AUTHOR), Vekhoff, Anne17 (AUTHOR), Tournilhac, Olivier18 (AUTHOR), Banos, Anne19 (AUTHOR), Oya, Hervé20 (AUTHOR), Lejeune, Julie21 (AUTHOR), Ouzegdouh, Maya1 (AUTHOR), Chevret, Sylvie21 (AUTHOR) |
| Source: | Leukemia & Lymphoma. 2017, Vol. 58 Issue 11, p2615-2623. 9p. 1 Diagram, 2 Charts, 4 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
